HOOKIPA board member Lengauer to depart; appoints Timothy Reilly as director

HOOKIPA Pharma Inc.

Christoph Lengauer will not stand for re-election at June 30, 2022 annual meeting; departure not due to disagreement.
Timothy Reilly, Ph.D. appointed to board effective immediately; will serve as Class II director until 2024.
Reilly previously SVP at Bristol Myers Squibb, currently Chief Development Officer at HotSpot Therapeutics.
As non-employee director, Reilly receives initial option for 19,200 shares plus annual $40,000 cash retainer.
Reilly will join Nominating and Corporate Governance Committee on June 30, 2022.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy Reilly

Director

HOOK · HOOKIPA Pharma Inc.

Effective: 2022-04-15
Filed: April 20, 2022, 7:59 PM ET

On April 15, 2022, the Board appointed Timothy Reilly, Ph.D. as a director of the Board, effective immediately.

Departed

Christoph Lengauer

Director

HOOK · HOOKIPA Pharma Inc.

Effective: 2022-06-30
Successor: Timothy Reilly
Filed: April 20, 2022, 7:59 PM ET

On April 15, 2022, Christoph Lengauer, a member of the board of directors (the “Board”) of HOOKIPA Pharma Inc. (the “Company”), notified the Company that he will not stand for re-election to the Board when his term expires at the Company’s 2022 annual meeting of shareholders on June 30, 2022 (the “2022 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy Reilly was appointed as Director at HOOKIPA Pharma Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 15, 2022, the Board appointed Timothy Reilly, Ph.D. as a director of the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christoph Lengauer departed as Director at HOOKIPA Pharma Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

On April 15, 2022, Christoph Lengauer, a member of the board of directors (the “Board”) of HOOKIPA Pharma Inc. (the “Company”), notified the Company that he will not stand for re-election to the Board when his term expires at the Company’s 2022 annual meeting of shareholders on June 30, 2022 (the “2022 Annual Meeting”).

View on SEC.gov

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-047835

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.